Crystalline forms of an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1

US8618112B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Joseph E. Lynch · Plainfield, US
• Yuri Y. Bereznitski · South River, US
• Frederick T. Mattrey · Bound Brook, US
• John L. Leazer, Jr. · Metuchen, US
• Russell R. Ferlita · Westfield, US
• Jinchu Liu · Edison, US
• Jungjun Yin · Green Brook, US
• Robert Wenslow · Plainsboro, US

Key dates

• Filing date: Dec 7, 2009
• Grant date: Dec 31, 2013
• Expiry date: May 24, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole are potent inhibitors of 11β-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.